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Background: Hashimoto's thyroiditis (HT) is an autoimmune disease characterized by chronic inflammation of
thyroid gland. Although HT is the most common cause of hypothyroidism, the pathogenesis of this disease is not
fully understood. Glycosylation of serum proteins was examined in HT only to a limited extent. The study was
designed to determine the glycosylation pattern of IgG-depleted sera from HT patients.
Methods: Serum N-glycans released by N-glycosidase F (PNGase F) digestion were analyzed by normal-phase
high-performance liquid chromatography (NP-HPLC). N-glycan structures in each collected HPLC fraction were
determined by liquid chromatography-mass spectrometry (LC-MS) and exoglycosidase digestion. Fucosylation
and sialylation was also analyzed by lectin blotting.
Results: The results showed an increase of monosialylated tri-antennary structure (A3G3S1) and disialylated
diantennary N-glycan with antennary fucose (FA2G2S2). Subsequently, we analyzed the serum N-glycan profile
by lectin blotting using lectins specific for fucose and sialic acid. We found a significant decrease of Lens culinaris
agglutinin (LCA) staining in HT samples, which resulted from the reduction of α1,6-linked core fucose in HT
serum. We also observed an increase of Maackia amurensis II lectin (MAL-II) reaction in HT due to the elevated
level of α2,3-sialylation in HT sera.
Conclusions: The detected alterations of serum protein sialylation might be caused by chronic inflammation in
HT. The obtained results complete our previous IgG N-glycosylation analysis in autoimmune thyroid patients
and show that the altered N-glycosylation of serum proteins is characteristic for autoimmunity process in HT.
General Significance
Thyroid autoimmunity is accompanied by changes of serum protein sialylation.
1. Introduction
Hashimoto's thyroiditis (HT) belongs to autoimmune thyroid dis-
eases (AITD), the group of the organ-specific autoimmune disorders
characterized by lymphocytic infiltration of the thyroid tissue [1]. Most
of HT patients produce antibodies against thyroid antigens, mainly
thyroid peroxidase (TPO) and thyroglobulin (Tg). Anti-thyroid anti-
bodies mediate an immune response which leads to tissue damage.
Except for an imbalanced iodide intake, HT is the most common cause
of hypothyroidism [2]. There are genetic and environmental
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susceptibility factors for HT. Several genes related to immune response
together with the gene encoding Tg have been reported as genetic
factors associated with HT [1,3]. Infections, allergy, smoking, toxins,
and irradiation belong to its environmental factors [4]. It is assumed
that loss of self-tolerance characteristic for autoimmune diseases is a
result of a dysregulated balance between the activity of Th17 and Th10
lymphocytes [5], which was also reported for AITD [6].
N-glycosylation is a common posttranslational protein modification.
During the N-glycan synthesis, the oligosaccharide precursor is further
modified by the action of several glycosidases and glycosyltransferases.
The composition of oligosaccharides, type of linkages between mono-
mers, and a number of branching are the source of the variety of N-
glycan structures, which belong to three basic groups: high-mannose/
oligomannose, hybrid and complex structures. Common N-glycan
modifications include the addition of sialic acid (SA) at the terminal
position of oligosaccharide chain, named sialylation and an attachment
of fucose (Fuc) both to the core structure and antennas in the outer part
of N-glycans, known as fucosylation [7,8].
Human serum N-glycoproteome consists of proteins secreted by all
body tissues, but its primary sources are liver and plasma cells. The
most abundant human serum glycoproteins are immunoglobulins (Ig),
transferrin, and α2-macroglobulin. N-glycans play a significant role in
the modulation of properties and functions of serum glycoproteins. The
oligosaccharide part can modify solubility, half-life time, and con-
formation of proteins as well as their mutual interactions [9]. Over the
last two decades, the serum N-glycome analysis became a popular ob-
ject of interest in search of new disease biomarkers. Changes of serum
N-glycan profile have been demonstrated mainly in cancers [10–12]
and inflammatory disorders [13]. N-glycosylation alterations in chronic
inflammation, including autoimmune diseases, have been reported for
several serum proteins. Among them, N-glycosylation of IgG was shown
to be the valuable indicator of rheumatoid arthritis (RA) [14], systemic
lupus erythematosus (SLE) [15] and inflammatory bowel disease (IBD)
[16]. The reduced galactosylation of IgG in RA is the best-characterized
serum glycomarker [17]. Among less abundant serum glycoproteins,
inflammation-related changes of N-glycosylation were shown for α1-
acid glycoprotein (AGP) and α2-macroglobulin. The increased level of
di- and tetra-antennary structures and the elevated monofucosylation of
di- and tri-antennary N-glycans on AGP were observed in chronic in-
flammation [18]. The content of mannose (Man) and galactose (Gal)
was significantly higher on α2-macroglobulin purified from serum
samples of SLE patients in comparison to healthy donors [19]. It was
shown that a change in glycosylation of a single protein in in-
flammatory conditions is a result of global serum N-glycome re-
arrangements [20,21]. Many studies have demonstrated that the de-
tection of disease-related glycan changes is also possible at the level of
whole serum N-glycome analysis. Liquid chromatography-mass spec-
trometry (LC-MS) analysis of N-glycans released from whole serum
proteins showed the decrease of fucosylated mono-galactosylated dia-
ntennary structures and the increase of tri-antennary galactosylated
glycans in RA female patients compared with healthy control [22]. In
Crohn's disease (CD) and ulcerative colitis (UC), two chronic IBDs, the
total plasma N-glycome was also shown to be changed. The decrease of
galactosylation accompanied by the enhanced sialylation of dia-
ntennary fucosylated structures and α2,3-sialylation of tri-antennary
fucosylated structures was observed in CD. The reduced fucosylation of
Table 1
List of lectins specific to sialylated and fucosylated glycans used in lectin blotting.
Name Abbreviation Sugar specificity Blocking solution Vector, Cat. No.
Aleuria aurantia lectin AAL Fuc α1,6-linked to GlcNAc 0.5M L-Fuc B-1395
Fuc α1,3-linked to LacNAc
Lens culinarins agglutinin LCA Fuc α1,6-linked to GlcNAc – B-1045
Ulex europaeus agglutinin I UEA-I α-linked Fuc 0.5M L-Fuc B-1065
Maackia amurensis lectin II MAL-II α2,3-linked SA – B-1265
Sambucus nigra agglutinin SNA α2,6-linked SA 1M acetic acid B-1305
Fig. 1. The efficiency of IgG depletion from human serum using Protein G Spin Plate (Thermo Scientific, 45-204). (A) Representative CBB profile of proteins in whole
serum, IgG-depleted serum and purified IgG. (B) The intensity of both IgG chains was not change after reapplication of IgG-depleted serum on Protein G Spin Plate.
Serum (10 μg) and IgG (1 μg) samples were resolved by 10% SDS-PAGE under reducing conditions. Molecular masses of IgG heavy and light chains were verified
using (A) Precision Plus Protein™ Dual Color Standards (Bio-Rad, 1-610-374) and (B) Page Ruler Prestained Protein Ladder (Thermo Scientific, 26-616).
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diantennary structures was detected in serum proteins from UC pa-
tients. In both IBDs, the higher serum protein sialylation was found
[23]. The altered serum or plasma N-glycome has been proven for
chronic diseases such as schizophrenia [24], chronic hepatitis [25], and
numerous types of cancer [12,26,27].
Our recent study showed for the first time a decreased IgG core
fucosylation in AITD patients compared to healthy volunteers and the
correlation of the reduced fucosylation with serum anti-TPO titer. We
also observed lower terminal fucosylation of the peripheral blood
mononuclear cells (PBMCs) in HT patients (Martin et al., unpublished
data). Our current studies on N-glycoproteins in HT IgG-depleted sera
are the continuation of the previous research focused on IgG N-glycans.
We used the sera after IgG depletion to enhance the signal from the less
abundant serum N-glycoproteins. The study aimed to characterize the
protein N-glycome of IgG-depleted serum samples from HT patients and
assess its potential changes in relation to healthy control. The com-
parative analysis of serum N-glycosylation was performed by lectin
profiling of SDS-PAGE separated glycoproteins and normal-phase high-
performance liquid chromatography (NP-HPLC). The detailed N-glycan
structures were identified using LC-MS/MS.
2. Materials and methods
2.1. Study population
51 Hashimoto's thyroiditis female patients (mean age 36.4 ± 12.8)
and 41 sex-matched healthy volunteers (mean age 31.9 ± 8.7) were
recruited to the study based on medical history, serum level of TSH,
anti-TPO, anti-Tg, and thyroid ultrasonography. The groups were age-
matched, and no significant difference in age between them was iden-
tified (P-value> .05). Blood samples were collected between May 2014
and July 2015 at the Endocrinology Clinic of the University Hospital in
Krakow. Subjects with other autoimmune diseases, other thyroid dis-
eases, and pregnant women were excluded. The study was approved by
the Bioethics Committee of the Jagiellonian University. Informed
written consent was given by all study participants.
Fig. 2. NP-HPLC analysis of 2-AB-labeled N-oligosaccharides released from serum glycoproteins of Hashimoto's thyroiditis patients. (A) The representative chro-
matogram is showing the separation of the N-glycome into 25 individual peaks (peak ID). Schematic structure representations were prepared using GlycoWorkbench;
red triangle, fucose; yellow circle, galactose; green circle, mannose; blue square, N-acetylglucosamine; purple diamond, sialic acid. (B) The effect of glycan digestion
with bovine kidney α1-2,4,6 fucosidase (BKF), Clostridium perfringens α2-3,6,8 neuraminidase (NanI) and bovine testes β1-3,4 galactosidase (BTG). (C) The com-
parison of relative glycan content of peak 22 between control and HT samples showing statistically significant upregulation of glycans in HT (p= .048). For statistical
analysis, the data were logit-transformed, and the Wilcoxon rank sum (Mann Whitney U) test was applied between the control group and HT group (p≤ .05 was
considered as statistically significant).
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Table 2
List of the most abundant glycan compositions detected in each HPLC fraction. Glycan structural features are proposed based on GU values compared with GlycoStore
database and on mass spectrometry (m/z values, complemented by MS2 data were applicable). The structures recognized as the major composition in each glycan
peak (GP) are framed. Schematic structure representations were prepared using GlycoWorkbench; red triangle, fucose; yellow circle, galactose; green circle, man-
nose; blue square, N-acetyglucosamine; purple diamond, sialic acid. The abbreviations to the second column: Ac, acetylation; F, fucose; GA, glucuronic acid; H,
hexose; N, HexNac. The abbreviations to the fourth column: A1-4, number of antennae; B, bisecting N-acetyglucosamine; F, fucose; G, galactose, M, mannose; S, sialic
acid.
(continued on next page)
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2.2. Serum sample collection
Blood was collected via venous puncture into S-Monovette serum
tubes (Sarstedt, 05.1557.001). Blood samples were left at room tem-
perature for five hours for blood coagulation and then were centrifuged
at 1200×g for 10min (Heraeus). Serum samples were stored in deep
freezing.
2.3. IgG depletion
Serum was diluted 1:1 with the binding buffer (0.1M Na2HPO4,
0.15M NaCl, pH 7.5). 20 μl of each diluted sample was applied to the
Protein G Spin Plate (Thermo Scientific, 45-204) and incubated 15min.
at room temperature on the orbital shaker (JW Electronic). Then 20 μl
of the binding buffer was added to each well and incubated for the next
Table 2 (continued)
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15min. After incubation, the plate was centrifuged (1000×g, 1 min.).
The flow-through fraction containing IgG-depleted serum was collected
and deeply frozen until the experiment.
2.4. Coomassie brilliant blue staining
The efficiency of IgG depletion from human sera was assessed by
Coomassie Brilliant Blue (CBB) staining. Whole serum and IgG-depleted
serum proteins (10 μg), and purified IgG (1 μg) were resolved by 10%
SDS-PAGE under reducing conditions followed by CBB staining (Sigma-
Aldrich, B-2025). Molecular masses of IgG heavy and light chains were
verified using Precision Plus Protein™ Dual Color Standards (Bio-Rad,
1610374) or Page Ruler Prestained Protein Ladder (Thermo Scientific,
26616).
2.5. Normal-phase high-performance liquid chromatography (NP-HPLC)
2.5.1. PNGase digestion
40 μl of diluted serum was reduced with 2.5 μl 200mM dithio-
threitol (DTT, Sigma-Aldrich) and incubated at 60 °C for 45min. After
cooling down to room temperature (RT), 10 μl of iodoacetamide (IAA,
Sigma-Aldrich) was added and incubated in darkness for 1 h in room
temperature. Then 2.5 μl of DTT was added again to serum proteins.
Samples were diluted by adding 100 μl of the binding buffer and 300 μl
of Milli-Q water. Then 100mU of PNGase F (Sigma-Aldrich, P-7367)
was added, and serum glycoproteins were deglycosylated overnight at
37 °C. Following PNGase digestion, 10% trifluoroacetic acid (TFA,
Fluka) was added to each sample, and the released N-glycans were
cleaned-up using C18 SPE column (Supelco) and subsequently
Carbograph SPE column (Supelco) according to Biskup et al. (2013)
[28]. Purified N-glycans were dried down by lyophilization (Labconco).
2.5.2. 2-AB labeling
Anthranilic acid amide (2-AB) (Sigma-Aldrich) and sodium
cyanoborohydride (Fluka) were dissolved in acetic acid, and DMSO
(3:2) mixture and 10 μl of the labeling solution was added to the dried
N-glycans and incubated at 65 °C for 3 h. After cooling down to RT, the
excess of labeling solution was removed using Spe-ed SPE Cartridges
(Applied Separation), and 2-AB-labeled N-glycans were eluted in Milli-
Q water, according to Link-Lenczowski et al. (2018) [29]. Purified N-
glycans were dried down by lyophilization and stored at −70 °C before
analyses by HPLC and MS.
2.5.3. Exoglycosidase digestion
50 μl of 2-AB-labeled N-glycans were dried down in SpeedVac
centrifuge (Savant) and treated with bovine kidney α1-2,4,6 fucosidase
(BKF), Clostridium perfringens α2-3,6,8 neuraminidase (NanI), and bo-
vine testes β1-3,4 galactosidase (BTG) (New England Biolabs). The
exoglycosidase digestion was performed according to the manufac-
turer's protocol at 37 °C overnight. To remove enzyme protein from the
samples Amicon Ultra 10 K (Millipore) centrifugal filters were used.
After cleaning step, digested N-glycans were dried down in SpeedVac
concentrator (Savant).
2.5.4. NP-HPLC analysis
2-AB-labeled N-glycans were separated on Tosoh TSK gel-Amide 80
column (4.6× 150mm, 3 μm bead size) (Tosoh Bioscience, Griesheim,
Germany) using Shimadzu Prominence HPLC system (Shimadzu) with
RF-20Axs fluorescence detector. Solvent A was acetonitrile (ACN), and
solvent B was 50mM ammonium hydroxide in Milli-Q water, titrated to
pH 4.4 with formic acid. The samples were loaded in 70% ACN and the
chromatography was performed using high-resolution binary gradient
under following conditions: temp=50 °C; flow rate= 1.25ml/min;
time=0min (t=0), 30% B; t=30.25, 48% B; t=31, 100% B; t=33,
100% B; t=34, 30% B; t=40, 30% B. The chromatographic system
was under control of Shimadzu LabSolutions 5.90 software. After each
set of 10 samples, the external standard (2-AB-labeled glucose oligomer
ladder; Glyko Prozyme) was separated. HPLC chromatograms were
integrated into 25 glycan peaks. The annotation of glycan peaks was
performed basing on mass spectrometry analysis and their glucose units
(GU) values compared to GlycoStore database (www.glycostore.org)
[30,31]. The percentage area of each peak represents its relative con-
tent within the chromatogram.
2.6. Liquid chromatography-mass spectrometry
NP-HPLC peaks were manually fractionated, concentrated by eva-
poration and reconstituted in 10 μl of ultrapure water. Liquid chro-
matography-mass spectrometry (LC-MS) analysis of concentrated NP-
HPLC fractions were performed using nanoACQUITY UPLC system from
Waters (Waters, Massachusetts, USA) coupled to a Compact mass
spectrometer (Bruker Daltonics, Bremen, Germany) as described before
[32]. Briefly, the chromatography system consists of a reverse phase
trap column (Acclaim PepMap C18, 1mm×300μm i.d., Thermo Fisher
Scientific) and of an analytical column (Halo C18 nano-LC column;
150mm×75μm i.d., 2.7μm HALO fused core particles; Advanced
Materials technology, USA). The separation was performed using 0.1%
formic acid in water as solvent A and 95% acetonitrile as solvent B at
the 1 μl/min flow rate. The LC system was coupled via online capillary
electrophoresis (CE) ESI-MS sprayer source (Agilent, California, USA) to
a Compact mass spectrometer operated in the positive ion mode. Glycan
compositions were assigned using GlycoWorkbench [33] and Glyco-
mode (http://web.expasy.org/glycomod/) according to obtained MS
and MS/MS spectra.
2.7. Lectin blotting
The set of selected lectins (Vector Lab.) were used to assess serum
protein fucosylation and sialylation. The lectins blocked by specific
sugars were used as the negative controls (Table 1). Lectin blotting was
Supplementary Fig. 1. The comparative analysis of total sialylation between
control group and Hashimoto's thyroiditis patients (HT). The total sialylation
was measured as a sum of relative intensities of the HPLC glycan peaks with the
annotated sialylated oligosaccharides (GP8,11,12,14-25). For statistical ana-
lysis, the data were logit-transformed, and the Wilcoxon rank sum (Mann
Whitney U) test was applied between the control group and HT group (p≤ .05
was considered as statistically significant).
M. Ząbczyńska, et al. BBA - General Subjects 1864 (2020) 129464
6
performed as described by Hoja-Łukowicz et al. (2013) [34]. Briefly,
10 μg of IgG-depleted serum proteins or whole serum proteins were
boiled in Laemmli sample buffer (Bio-Rad Lab.) with 5% β-mercap-
toethanol for 5min. and separated on 10% stain-free gels (Bio-Rad
Lab.). The resolved proteins were visualized on gels using Gel Doc EZ
Imaging System with Image Lab software (Bio-Rad Lab.). Then the
proteins were electroblotted to the PVDF membranes (Millipore), and
the blots were blocked overnight using Carbo Free Blocking Solution
(Vector Lab.) to avoid nonspecific binding. After washing three times
with TBS, the blots were incubated for 1 h with the lectins followed by
incubation with alkaline phosphatase-conjugated ExtrAvidin (Sigma-
Aldrich, E-2636) for 1 h at RT. Glycoprotein bands were visualized by
the colorimetric reaction catalyzed by alkaline phosphatase. The in-
tensity of lectin staining on each lane was measured densitometrically
and was normalized to the protein signal on corresponding gel lanes
using Image Lab software (Bio-Rad Lab.). The lectin blotting was
performed in duplicates or triplicates.
To determinate the signal from O-glycans we performed PNGase
digestion followed by the lectin blotting. IgG-depleted serum (10 μg) in
the phosphate buffer (50mM Na2HPO4, pH 7.5) was reduced by adding
1 μl 5% SDS and incubated at 100 °C for 3min. After cooling down 1.5
μl of Nonidet P-40 (Fluka) and 0.5 U of PNGase F (Sigma-Aldrich, P-
7367) were added, and incubated overnight at 37 °C. PNGase-digested
and untreated serum samples were resolved on 10% SDS-PAGE and
destined to lectin blotting. Non-specific lectin reaction was verified by
the pre-incubation of lectin with specific sugar (0.5 M fucose for AAL
and UEA-I; 0.2M lactose in 0.4M acetic acid for SNA) or glycophorin, a
protein bearing sialylated glycans (Sigma-Aldrich, G-9511, diluted
1:500 for MAL-II).
Fig. 3. ESI-MS/MS spectra of precursor ions from peak 22 fraction collected from NP-HPLC. The suggested glycan structures are given in rectangles. The fragment ion
at m/z 657.2 in A, B and C is indicative for terminally sialylated antennas, fragment ion at m/z 803.2 clearly indicates the presence of fucosylated antenna in A.
Schematic structure representations were prepared using GlycoWorkbench; red triangle, fucose; yellow circle, galactose; green circle, mannose; blue square, N-
acetylglucosamine; purple diamond, sialic acid.
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2.8. Statistical analysis
Glycan HPLC data represent the relative percentage areas derived
from the chromatogram (% area), with the sum of the values to a
constant value at 100% (or 1). First, based on quality control, one
sample was discarded. Then we applied a logit transform (logit
(peak)= log(peak/(1-peak))) on different data. A non-parametric sta-
tistical hypothesis test, Wilcoxon rank sum (Mann Whitney U) test, was
applied between the control group and HT group for each peak of the
chromatogram. P-values obtained from Mann Whitney U test were FDR-
corrected using the method of Benjamini and Hochberg (1995) [35].
Results with an FDR of< 5% were considered statistically significant
whereas results with P-value non-adjusted< 5% were considered sta-
tistically nominal significant.
Glycan lectin data represent the intensity of lectin staining mea-
sured densitometrically for each line and normalized to the protein
signal on the corresponding gel lane. Lectin tests have been performed
on different PVDF membranes and batches. Consequently, we analyze
the association between lectin value with AITD status using a linear
mixed model with age as fixed effect and individual, membrane, and
batch as a random effect. P-values obtained from the ANOVA test were
FDR-corrected using the method of Benjamini and Hochberg (1995)
[35]. Results with an FDR of< 5% were considered statistically sig-
nificant whereas results with P-value non-adjusted<5% were con-
sidered statistically nominal significant.
3. Results
Depletion of IgG from human serum samples was performed using
protein G resin plate. The serum volume was experimentally established
to remove IgG efficiently (Fig. 1). CBB profiles showed that majority of
IgG was depleted from serum sample (Fig. 1A). After reapplication of
IgG-depleted serum on the Protein G Spin Plate (Thermo Scientific) the
intensity of protein bands corresponding to both IgG chains was un-
changed in CBB profile (Fig. 1B) which suggests that other proteins with
similar molecular weight are present in the bands corresponding to IgG
heavy and light chains. IgG-depleted sera were destined to the analysis
of glycan structure by HPLC, LC-MS and lectin blotting. These methods
represent two different analytical approaches to N-glycan profiling.
HPLC and LC-MS analyze released N-glycans while in lectin blotting
specific glycoepitopes on SDS-PAGE separated glycoproteins are de-
tected.
NP-HPLC was performed to compare the N-glycan profiles for IgG
depleted-sera from HT patients and healthy donors. The obtained
chromatograms were manually integrated into 25 separated glycan
peaks (GPs). The representative HPLC chromatogram is shown in
Fig. 2A. N-glycan HPLC pattern was uniform for HT and control samples
with predominant GP16 observed at GU 8.15. For the detailed struc-
tural analysis, N-glycans were fractionated by NP-HPLC according to
the retention time of the integrated peaks. Each HPLC fraction was
collected and destined to determine N-glycan composition by LC-MS.
Three pairs of the close located neighboring peaks (GP11/12, GP17/18,
and GP19/20) were pooled because it was impossible to separate them
during manual collection of the fractions. Table 2 presents N-glycans
assigned to the GPs, except for GP1 and GP2 with the lowest intensity in
NP-HPLC chromatograms. The structures recognized as the major
composition in each GP are framed. The majority of N-glycans are the
complex structures (di- to tetra-antennary) with mono- or disialylated
antennas. Five fucosylated N-glycans were identified, and among them,
three contains antennary Fuc residues.
The relative intensity of each GP was expressed as an area percent
(% area) of the total integrated area. For statistical analysis the data
were transformed using (logit(peak)= log(peak/(1-peak))) formula,
where peak corresponds to % area. The total sialylation of HT serum
proteins measured as a sum of relative intensities of the peaks with the
annotated sialylated structures (GP8,11,12,14–25) was reduced in re-
lation to control group, but this change was not statistically nominal
significant (p= .291) (Supplementary Fig. 1). The comparison of re-
lative intensities for each peak separately showed a statistically sig-
nificant increase of the GP22 (GU 9.51) abundance in HT samples
(p= .048) (Fig. 2C). Two major N-glycan structures: monosialylated
tri-antennary glycan (A3G3S1; m/z 1209.40) and disialylated dia-
ntennary structure with antennary Fuc (FA2G2S2; m/z 1245.42) were
identified using LC-MS/MS analysis as the ones contributing to the FLR
signal of the GP22. Third structure assigned to GP22 (A2G2S2) was co-
eluted from the neighboring fraction of GP21. The LC-MS/MS spectra
for N-glycans assigned to GP22 are presented in Fig. 3. The two pre-
dominant HPLC peaks GP16 and GP21 contain the complex-type dia-
ntennary monosialylated (GP16, A2G2S1) and disialylated (GP21,
A2G2S2) N-glycan structures. For the rest of HPLC GPs the statistically
significant differences were not found (Supplementary Fig. 2).
The HPLC peak annotation was additionally verified by the analysis
of the exoglycosidase-digested N-glycans. We observed the evident shift
of the GP16 and GP21 after treatment with α2–3,6,8 neuraminidase
Supplementary Fig. 2. The comparison of relative glycan content of HPLC peaks (GP1-21, 23-25) between control and Hashimoto′s thyroiditis patients (HT). For
statistical analysis, the data were logit-transformed, and the Wilcoxon rank sum (Mann Whitney U) test was applied between the control group and HT group (p≤ .05
was considered as statistically significant).
Supplementary Fig. 3. Representative HPLC chromatograms of N-glycans derived from the whole serum and IgG-depleted serum of healthy donor (control) and
Hashimoto's thyroiditis patient. N-glycans were enzymatically liberated from serum proteins, 2-AB labeled and analyzed by NP-HPLC with fluorescent detection.
Glycans peak indications correspond to the peak ID numbers presented in Fig. 2.
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(NanI). The intensity of GP16 was not changed and GP21 was partially
reduced when α1–2,4,6 fucosidase (BKF) was applied. In the case of
GP22, the effect of NanI and BKF was not as clearly visible due to the
overlapping of peaks being the products of digested GP23-GP25. This
was confirmed when β1–3,4 galactosidase (BTG) together with the
sialidase was applied (Fig. 2B).
N-glycans liberated from whole serum proteins and IgG-depleted
serum proteins were also compared (Supplementary Fig. 3). The chro-
matographic profiles of both sample types are similar suggesting that no
evident qualitative differences are present. However, some qualitative
variations between the whole serum and IgG-depleted serum glycomes
were observed, particularly in case of GP8-10. Additionally, a slightly
different retention time of GP22 in the profiles of whole serum and IgG-
depleted serum was found. It would indicate that in this retention time
area the N-glycans from both samples separate slightly differently.
Taking into account also the quantitative differences in GP22 between
control and HT samples (Fig. 2C), looking for glycosylation changes in
IgG-depleted serum seems to be reasonable. Otherwise, these
differences could be masked by IgG-derived glycans.
Complementary to HPLC, the lectin blotting analysis was performed
using set of biotinylated lectins specific for SA and Fuc residues (Fig. 4).
Comparative lectin staining of the whole serum and IgG-depleted serum
proteins showed a significantly or completely reduced intensity of
bands corresponding to IgG heavy and light chains (Supplementary
Fig. 4) which confirmed that IgG was efficiently removed from serum.
The profile of SDS-PAGE-resolved serum proteins was quantitatively
comparable for C and HT samples (Supplementary Fig. 5). To stan-
dardize data, obtained in each experiment and on each PVDF mem-
brane, the values from the densitometric analysis were transformed
using the model described in Materials and methods, and the ANOVA
test was performed. The lectin staining revealed the differences in the
intensity of single protein bands between the IgG-depleted serum
samples (Fig. 4). However, they were specific for individual donors. The
sialylation and fucosylation of serum proteins were compared between
control and study groups by measuring the intensity of the lectin re-
action with all separated glycoproteins for one sample normalized to
Fig. 4. Lectin analysis of serum glycan fucosylation (A-C) and sialylation (D, E). IgG-depleted serum proteins from healthy individuals (C, n=20) and Hashimoto's
thyroiditis patients (HT, n=20) separated on stain-free gels, were incubated with the lectins specific for fucose (LCA, AAL, UEA-I) and sialic acid (MAL-II, SNA).
Fucosylated and sialylated glycoproteins were visualized colorimetrically. Molecular masses were verified using Precision Page Ruler Prestained Protein Ladder
(Thermo Scientific, 26616). The intensity of lectin staining on each lane was measured densitometrically and was normalized to the protein signal on corresponding
gel lanes. P-values from the ANOVA test were FDR-corrected and the results with an FDR of< 5% were considered statistically significant (p= .042 for LCA,
p= .031 for MAL-II). Schematic structure representations were prepared using GlycoWorkbench; red triangle, fucose; yellow circle, galactose; green circle, mannose;
blue square, N-acetylglucosamine; purple diamond, sialic acid.
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the intensity of proteins measured in stain-free gels. The statistical
analysis showed a significant decrease in the densitometric signal for
LCA reaction in HT samples (p= .042). The weaker LCA staining cor-
responds to the reduction of the α1,6-linked core fucosylation in HT
serum glycoproteins (Fig. 4A). We also observed the statistically sig-
nificant increase of MAL-II reaction in HT (p= .031), which results
from the elevated level of α2,3-sialylation in HT sera (Fig. 4D). The
comparison of AAL, UEA-I, and SNA staining between C and HT sam-
ples showed no statistically significant differences with p= .40,
p= .83, p= .97, respectively (Fig. 4 B, C, E). In the analysis with fu-
cose-specific lectins we did not observe a signal from PNGase treated
samples after reaction with LCA and a weak signal for UEA-I and AAL
(Supplementary Fig. 6A). Whereas in case of lectins specific for sialy-
lated glycans we found the positive SNA and MAL-II reaction with
PNGase-treated serum proteins, which indicates on the presence of
α2,6- and α2,3-sialylated O-glycans (Supplementary Fig. 6B).
Taken together, the enhanced α2,3-sialylation found in MAL-II
blotting and the increase of the sialylated diantennary structures as-
signed to GP22 detected by NP-HPLC suggest that the α2,3-sialylation
of serum proteins is increased in the course of Hashimoto's thyroiditis.
4. Discussion
Changes of protein glycosylation have been reported to be strongly
associated with the progression of many types of human cancers [36]
and inflammatory diseases [13]. For that reason, N-glycosylation is
taken into consideration as a marker of different types of human dis-
orders. The alterations of protein glycosylation profile in pathological
conditions have been analyzed for cellular [37] and secreted proteins
[38,39]. For clinical practice; however, it is important to look for glyco-
biomarkers in fluid body samples, and analyses of human serum are
currently the main focus in this field.
Glycosylation of serum proteins in Hashimoto's thyroiditis has been
poorly studied so far and only IgG, as the main serum glycoprotein has
been analyzed. The previous research showed that the core fucosylation
of anti-Tg IgG in HT patients was lower than in Graves' disease (GD)
and papillary thyroid carcinoma (PTC) donors [40] and higher than in
healthy individuals [41]. The content of Man, terminal SA, and
Galβ1,4GlcNAcβ1,2Man structure in anti-Tg was also significantly
elevated in HT compared to healthy control [41]. The enhanced sialy-
lation and fucosylation of anti-Tg were correlated with the titer of this
antibody in HT patients' sera [41]. Our recent research, in turn, de-
monstrated a decrease of IgG fucosylation in AITD patients, and we
suggested that it might determine more potent antibody-dependent cell-
mediated cytotoxicity (ADCC) reaction in Hashimoto's thyroid tissue
(Martin et al., unpublished data). The changes of sialylation were also
proved for thyroid tissue of AITD patients with the use of the following
lectins: Tritrichomonas mobilensis lectin (TML) which recognizes SA
without linkage preferences as well as SNA and MAL-II specific for
α2,6- and α2,3-linked SA, respectively. The different MAL-II staining
profile of thyroid histochemical specimens from HT, GD, and healthy
donors was found. The expression of α2,3-linked SA in follicular cells,
especially in the luminal surfaces of their cell membrane, was higher in
HT and GD specimens than normal thyroid gland [42].
The present study focused on the identification of altered N-glycan
structures in HT IgG-depleted sera. We compared N-glycomes between
HT patients and healthy control using two different strategies: the
analysis of the released N-glycans and the study of N-glycosylated
Supplementary Fig. 4. Lectin blotting of the whole sera (1) and IgG-depleted sera (2) from healthy donors (C, control) and Hashimoto's thyroiditis patients (HT).
Serum samples (10 μg) were separated by 10% SDS-PAGE under reducing conditions. Molecular masses of IgG heavy chains were verified using Precision Plus
Protein™ Dual Color Standards (Bio-Rad, 1-610-374). IgG heavy chain is marked in a red frame. The bands corresponding to glycoproteins with the stronger staining
in IgG-depleted serum compared to the whole serum were marked by yellow arrowheads.
Supplementary Fig. 5. Protein profile of IgG-depleted sera from healthy do-
nors (C, control) and Hashimoto's thyroiditis patients (HT) obtained using stain-
free system (Bio-Rad). IgG-depleted serum proteins (10 μg) were resolved in
10% SDS-PAGE stain-free gels under reducing conditions. Page Ruler Prestained
Protein Ladder (Thermo Scientific, 26-616) was used as the protein standard.
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serum proteins. Both approaches showed that the sialylation of N-gly-
cans is altered in HT patients' serum proteins. The results indicated that
the sialylated complex-type N-glycans with antennary Fuc are more
abundant in HT serum proteins. Adding to that, the more intensive
reaction with α2,3-SA-specific MAL-II lectin in HT serum samples was
observed.
On the other hand, the total sialylation of N-glycans was slightly
reduced in HT, but this result was not statistically significant. LCA
lectin staining demonstrated the reduction of α1,6-fucosylation in HT
serum glycoproteins. This decrease of serum protein core fucosylation
corresponds with our previous results, which showed a reduction of
core α1,6-Fuc in IgG isolated from AITD patients (Martin et al., un-
published data). The increased level of the sialylated complex-type N-
glycans assigned to GP22 was not accompanied by the change of the
total serum sialylation. The glycosylation analysis was performed for a
mixture of secreted proteins produced by different tissues. The rela-
tively minor change of glycosylation identified by HPLC might concern
only a limited number of proteins which glycosylation is regulated by
the autoimmune process. Moreover, HPLC results reflect N-glycome
profile, whereas in lectin blotting both N- and O-glycans were analyzed
and for this reason, the results of the total sialylation and fucosylation
differ between these two analytical approaches.
The results obtained in the present study and the literature data
mentioned above show that the HT autoimmunity is accompanied by
the glycosylation changes of serum proteins. Taking into consideration
that the level of thyroid hormones and TSH is stable in HT patients due
to levothyroxine (T4) substitution, an immune response seems to be the
most probable cause of N-glycosylation changes. The alterations of total
plasma/serum N-glycosylation during an acute phase of inflammation
were described previously. Reiding and co-workers observed the re-
lationship between N-glycosylation of serum proteins and the clinical
markers of metabolic health and inflammation in healthy individuals
from the Leiden Longevity Cohort Study. A positive association between
the level of high sensitivity C reactive protein (hs-CRP) and tri- and
tetra-antennary N-glycans was identified. Furthermore, the enhanced
sialylation of fucosylated di- and tri-antennary N-glycans has been
proved to be correlated with the elevated hs-CRP level [43], which
corresponds to our HPLC results obtained for GP22 in HT and the
augmented α2,3-sialylation of HT serum glycoproteins demonstrated
by MAL-II blotting. The study by Reiding and co-workers indicated that
the fucosylation of diantennary N-glycans decreased with the higher hs-
CRP level, whereas the fucosylation of tri-antennary structures in-
tensified in this inflammation process [43]. Yasukawa et al. in the
mouse model of inflammation also showed that the change in con-
centration of acute phase proteins is accompanied by an alteration of
their sialylation profile. The liver expression of ST3Gal and ST6GalNAc
sialyltransferases was accelerated during inflammation and reduced to
the baseline level after inflammation silencing [44].
Altered glycosylation of single serum protein has been described in
autoimmune disorders. The analysis of transferrin, a negative acute
phase protein, showed a difference in serum concentration of its five
glycoforms in juvenile idiopathic arthritis (JIA), the most common
rheumatic condition in children. Transferrin glycoforms differed in SA
content between JIA and healthy subjects. The relative serum
Supplementary Fig. 6. Lectin analysis of fucosylation (A) and sialylation (B) in IgG-depleted serum from healthy control (C) and Hashimoto's thyroiditis (HT) after
PNGase digestion. IgG-depleted serum samples (10 μg) were de-N-glycosylated using PNGase (Sigma-Aldrich, P-7367) and separated by 10% SDS-PAGE under
reducing conditions. (A) LCA, UEA-I and AAL were used to analysis of fucosylation. (B) SNA and MAL-II were applied to detect sialic acid-bearing glycans. Molecular
masses were verified using Precision Plus Protein™ Dual Color Standards (Bio-Rad, 1610374).
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concentration of tetrasialotransferrin was significantly lower and pen-
tasialotransferrin significantly higher in JIA in comparison to controls
[45]. The analysis of serum protein N-glycosylation after im-
munotherapy was performed in patients with inflammatory arthritis.
Upregulation of the core-fucosylated, galactosylated diantennary
structures and a decrease of the sialylated tri-antennary glycans content
with and without antennary Fuc were observed after anti-TNF therapy
of patients with rheumatoid arthritis and psoriatic arthritis. The authors
suggested that N-glycosylation change of serum proteins is associated
with silencing of inflammatory processes as the result of anti-TNF
therapy [20]. The expression of glycosyltransferases, besides the
availability of sugar substrate and environmental factors, is the primary
regulator of oligosaccharide composition and branching. It was shown
that the glycosyltransferase expression is regulated by cytokines in in-
flammation states [46]. Exposure to IL-6 and IL-8 resulted in the higher
expression of FUT11, FUT3, ST6Gal2, and ST3Gal6 in human bronchial
mucosa [47]. An influence of TNFα on the expression of FUT3, FUT4,
ST3Gal3, and ST3Gal4 suggested the relation between chronic in-
flammation in cystic fibrosis and the altered glycosylation profile of
human airway mucins in the course of this disease [48]. The above
results prove the role of proinflammatory agents in glycosyltransferase
expression. The state of chronic inflammation in HT patients might also
affect the sialyltransferase expression in plasma and liver cells, the
primary sources of serum proteins.
Future studies are necessary to evaluate the functional con-
sequences of the observed sialylation changes in HT autoimmunity.
Based on the literature data, we can assume that the enhanced sialy-
lation of some serum proteins might be necessary for their interactions
with sialic acid-binding immunoglobulin-like lectins (Siglecs) present
on immune cells. Siglecs play a significant role in the regulation of
immune system [49,50] by binding SA-containing ligands widely dis-
tributed on the host and pathogenic cells [51]. One of the members
belonging to the Siglec family with proven ability to bind sialylated
plasma proteins is CD22, a B-cell surface receptor. Hanasaki and co-
workers showed that recombinant CD22 binds haptoglobin and IgM
from human plasma and this binding is blocked by α2,6-sialylated li-
gand or the sialidase treatment in case of IgM [52]. The further study
revealed that CD22 interaction with IgM-antigen complex influences B-
cell activation [53]. In the light of the described data and our results, it
seems likely that the altered sialylation of serum/plasma proteins in-
fluences immune cell activity via interaction of these sialoproteins with
Siglecs.
In conclusion, HPLC analysis of N-glycosylation of IgG-depleted
serum proteins followed by LC-MS N-glycan structure identification
allowed to detect the changes of serum protein sialylation in HT pa-
tients in comparison to healthy individuals. The altered sialylation has
been additionally confirmed by more intensive reaction with α2,3-SA-
specific MAL-II lectin in HT serum. The present results completed our
previous IgG N-glycosylation analysis in AITD patients, and both studies
clearly show that the altered N-glycosylation is an evident manifesta-
tion of autoimmunity process in HT.
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